Peking University: Lymphoma trials

The registry lists 20 Lymphoma studies with Peking University as lead sponsor. 2 are open to participants now and 0 have results posted.

Phase 1 6Phase 2 7Phase 3 1Phase 4 5No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• The Role of Consolidative Autologous Stem Cell Transplantation After First-line Therapy in Peripheral T Cell LymphomaRecruitingNCT04489264
• Pegaspargase-COEP Chemotherapy Combined With Radiotherapy for Extra-nodal NK/T Cell LymphomaRecruitingNCT04484506Phase 2
• Plerixafor for Poorly Mobilized LymphomaStatus unknownNCT05510544Phase 4
• R-MTX-zanbrutinib in Secondary CNS LymphomaStatus unknownNCT05398224Phase 2
• Dexamethasone, Azacytidine,Pegaspargase and Tislelizumab for NK/T Cell LymphomaStatus unknownNCT04899414Phase 2
• Efficacy and Safety of CDOP vs CHOP for Newly Diagnosed Peripheral T-cell LymphomaStatus unknownNCT03952572Phase 3
• MC-19PD1 CAR-T in Relapsed or Refractory B Cell LymphomaStatus unknownNCT03932955Phase 1
• PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell LymphomaStatus unknownNCT03701022Phase 2
• Study Evaluating the Safety and Efficacy of JWCAR029 in Adult Subjects With Relapsed and Refractory B-cell Non-Hodgkin LymphomaStatus unknownNCT03344367Phase 1
• Correlation Analysis of T-lymphocyte Subsets and Prognosis in Autologous Stem Cell Transplantation (ASCT) for LymphomaStatus unknownNCT03283111Not applicable
• Safety and Efficacy of iPD1 CD19 eCAR T Cells in Relapsed or Refractory B-cell LymphomaStatus unknownNCT03208556Phase 1
• Chidamide Plus DICE Regimen for Patients With Relapse or Refractory B-cell Non-Hodgkin's Lymphoma (NHL)Status unknownNCT03105596Phase 2
• Erythropoietin in the Treatment of Anemia After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT03010579Phase 4
• PEG-rhG-CSF in Lymphoma Patients After Autologous Hematopoietic Stem Cell TransplantationStatus unknownNCT02905942Phase 4
• Autologous CD19 CAR T Cells in Relapsed or Refractory B-cell LymphomaStatus unknownNCT02842138Phase 1
• CAR T Cells Targeting CD30 Positive Lymphomas (4SCAR30273)Status unknownNCT02274584Phase 1/2
• Evaluation of 4th Generation Safety-designed CAR T Cells Targeting High-risk and Refractory B Cell LymphomasStatus unknownNCT02247609Phase 1/2
• Hepatitis B Virus Reactivation After Withdrawal of Prophylactic Antiviral Therapy in Lymphoma PatientsCompletedNCT02108444
• Prophylactic Use of Entecavir for HBsAg Positive Lymphoma Patients Treated With Rituximab-based ImmunochemotherapyStatus unknownNCT01768195Phase 4
• Prophylactic Use of Entecavir for HBsAg Negative/HBcAb Positive/Hepatitis B Virus DNA Negative Patients With LymphomaStatus unknownNCT01765231Phase 4